Case report: Dupilumab leads to an increased chance of head and neck Staphylococcus aureus infection in atopic dermatitis patients

Dupilumab was the first biological medication licensed to treat atopic dermatitis (AD), and it has shown remarkable effectiveness and safety in the treatment of moderate-to-severe atopic dermatitis. There are limited drug-related adverse events associated with dupilumab in atopic dermatitis (AD) tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Min, Gao, Kai, Ali, Kamran, Shan, Jinpeng, Qiu, YunMi, Xie, Tianci, Yu, Yiling, Wu, Liming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031056/
https://www.ncbi.nlm.nih.gov/pubmed/36968828
http://dx.doi.org/10.3389/fmed.2023.1027589
_version_ 1784910518328229888
author Chen, Min
Gao, Kai
Ali, Kamran
Shan, Jinpeng
Qiu, YunMi
Xie, Tianci
Yu, Yiling
Wu, Liming
author_facet Chen, Min
Gao, Kai
Ali, Kamran
Shan, Jinpeng
Qiu, YunMi
Xie, Tianci
Yu, Yiling
Wu, Liming
author_sort Chen, Min
collection PubMed
description Dupilumab was the first biological medication licensed to treat atopic dermatitis (AD), and it has shown remarkable effectiveness and safety in the treatment of moderate-to-severe atopic dermatitis. There are limited drug-related adverse events associated with dupilumab in atopic dermatitis (AD) treatment. Here, we present two cases of local Staphylococcus aureus infection during the treatment of atopic dermatitis with dupilumab.
format Online
Article
Text
id pubmed-10031056
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100310562023-03-23 Case report: Dupilumab leads to an increased chance of head and neck Staphylococcus aureus infection in atopic dermatitis patients Chen, Min Gao, Kai Ali, Kamran Shan, Jinpeng Qiu, YunMi Xie, Tianci Yu, Yiling Wu, Liming Front Med (Lausanne) Medicine Dupilumab was the first biological medication licensed to treat atopic dermatitis (AD), and it has shown remarkable effectiveness and safety in the treatment of moderate-to-severe atopic dermatitis. There are limited drug-related adverse events associated with dupilumab in atopic dermatitis (AD) treatment. Here, we present two cases of local Staphylococcus aureus infection during the treatment of atopic dermatitis with dupilumab. Frontiers Media S.A. 2023-03-08 /pmc/articles/PMC10031056/ /pubmed/36968828 http://dx.doi.org/10.3389/fmed.2023.1027589 Text en Copyright © 2023 Chen, Gao, Ali, Shan, Qiu, Xie, Yu and Wu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Chen, Min
Gao, Kai
Ali, Kamran
Shan, Jinpeng
Qiu, YunMi
Xie, Tianci
Yu, Yiling
Wu, Liming
Case report: Dupilumab leads to an increased chance of head and neck Staphylococcus aureus infection in atopic dermatitis patients
title Case report: Dupilumab leads to an increased chance of head and neck Staphylococcus aureus infection in atopic dermatitis patients
title_full Case report: Dupilumab leads to an increased chance of head and neck Staphylococcus aureus infection in atopic dermatitis patients
title_fullStr Case report: Dupilumab leads to an increased chance of head and neck Staphylococcus aureus infection in atopic dermatitis patients
title_full_unstemmed Case report: Dupilumab leads to an increased chance of head and neck Staphylococcus aureus infection in atopic dermatitis patients
title_short Case report: Dupilumab leads to an increased chance of head and neck Staphylococcus aureus infection in atopic dermatitis patients
title_sort case report: dupilumab leads to an increased chance of head and neck staphylococcus aureus infection in atopic dermatitis patients
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031056/
https://www.ncbi.nlm.nih.gov/pubmed/36968828
http://dx.doi.org/10.3389/fmed.2023.1027589
work_keys_str_mv AT chenmin casereportdupilumableadstoanincreasedchanceofheadandneckstaphylococcusaureusinfectioninatopicdermatitispatients
AT gaokai casereportdupilumableadstoanincreasedchanceofheadandneckstaphylococcusaureusinfectioninatopicdermatitispatients
AT alikamran casereportdupilumableadstoanincreasedchanceofheadandneckstaphylococcusaureusinfectioninatopicdermatitispatients
AT shanjinpeng casereportdupilumableadstoanincreasedchanceofheadandneckstaphylococcusaureusinfectioninatopicdermatitispatients
AT qiuyunmi casereportdupilumableadstoanincreasedchanceofheadandneckstaphylococcusaureusinfectioninatopicdermatitispatients
AT xietianci casereportdupilumableadstoanincreasedchanceofheadandneckstaphylococcusaureusinfectioninatopicdermatitispatients
AT yuyiling casereportdupilumableadstoanincreasedchanceofheadandneckstaphylococcusaureusinfectioninatopicdermatitispatients
AT wuliming casereportdupilumableadstoanincreasedchanceofheadandneckstaphylococcusaureusinfectioninatopicdermatitispatients

Ejemplares similares